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Despite the introduction of tyrosine ki-
nase inhibitor therapy, the prognosis for
p190-BCR-ABL acute lymphoblastic leu-
kemia remains poor. In the present study,
we present the cellular and molecular
roles of the Rho GTPase guanine nucleo-
tide exchange factor Vav in lymphoid
leukemogenesis and explore the roles of
Vav proteins in BCR-ABL–dependent sig-
naling. We show that genetic deficiency
of the guanine nucleotide exchange fac-
tor Vav3 delays leukemogenesis by p190-
BCR-ABL and phenocopies the effect of
Rac2 deficiency, a downstream effector
of Vav3. Compensatory up-regulation of
expression and activation of Vav3 in Vav1/
Vav2–deficient B-cell progenitors in-
creases the transformation ability of p190-
BCR-ABL. Vav3 deficiency induces
apoptosis of murine and human leukemic
lymphoid progenitors, decreases the acti-
vation of Rho GTPase family members
and p21-activated kinase, and is associ-
ated with increased Bad phosphorylation
and up-regulation of Bax, Bak, and Bik.
Finally, Vav3 activation only partly de-
pends on ABL TK activity, and Vav3 defi-
ciency collaborates with tyrosine kinase
inhibitors to inhibit CrkL activation and
impair leukemogenesis in vitro and
in vivo. We conclude that Vav3 represents
a novel specific molecular leukemic effec-
tor for multitarget therapy in p190-BCR-
ABL–expressng acute lymphoblastic leu-
kemia. (Blood. 2012;120(4):800-811)
Introduction
Philadelphia chromosome–positive (Ph) hematologic malignan-
cies arise from the t(9,22) (q34;q11.2) mutation, which encodes the
constitutively active tyrosine kinase oncofusion protein BCR-ABL.
BCR-ABL is both necessary and sufficient to induce leukemia.1
Two types of BCR-ABL fusion proteins, associated with different
break points in the BCR gene, have been identified in patients
with Ph B-cell acute lymphoblastic leukemia (Ph B-ALL). A
190-kDa fusion protein, referred to as p190-BCR-ABL, is present
in 60%-80% of Ph B-ALL cases. Leukemia induced by this
BCR-ABL fusion protein arises from a transformed B-cell progeni-
tor.2 A BCR-ABL isoform of 210 kDa, known as p210-BCR-ABL,
is commonly expressed in patients with chronic myelogenous
leukemia (CML) and in a minority of patients with Ph B-ALL.
The transforming effect of BCR-ABL is dependent on the tyrosine
kinase (TK) activity of the fusion protein that leads to autophosphor-
ylation, recruitment of adaptor proteins, and subsequent activation
of downstream signaling. The TK inhibitor (TKI) imatinib and the
second-generation TKIs dasatinib and nilotinib have been used as
frontline treatment for CML and Ph B-ALL patients.3 However,
relapse is common in Ph B-ALL despite high rates of complete
response with initial therapy,4,5 probably because of survival of
leukemic progenitors. These BCR-ABL progenitors appear to
accumulate additional genetic mutations that result in a prolifera-
tive advantage and differentiation arrest.6 Understanding the down-
stream signaling cascades activated by BCR-ABL may lead to the
development of more effective therapeutic strategies that aim to
prevent the development and/or selection of TKI-resistant clones.
Expression of p210-BCR-ABL activates the Rho-family
GTPases Rac, RhoA, and Cdc42,7 possibly through the double
homology (DH) domain of guanine exchange factors (GEFs).8 We
demonstrated previously that the absence of Rac proteins, specifi-
cally Rac2 or the combination of Rac1 and Rac2, impairs myeloid
leukemogenesis induced by p210-BCR-ABL expression in the
hematopoietic stem and progenitor cell compartment.9,10 Activation
of Rac GTPases, particularly Rac2, has been shown to regulate
reactive oxygen species production by NADPH oxidase com-
plexes11 and possibly to be responsible for DNA damage and
genetic instability in BCR-ABL leukemias.12 Expression of p190-
BCR-ABL also activates Rac GTPases7 despite a lack of the DH
domain, suggesting that the activation of Rho-family GTPases by
p190-BCR-ABL must depend on the expression and activation of
alternative GEFs.
Vav proteins are GEFs for Rho-family GTPase members.13 The
mammalian Vav family is made up of 3 members: Vav1, Vav2, and
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Vav3. Despite common functional domains and similar mechanism
of phosphorylation-dependent activation,14 the sequence homology
between the 3 Vav isoforms is only approximately 65%. In
addition, Vav1 expression is restricted to hematopoietic cells,
whereas Vav2 and Vav3 are expressed broadly in multiple tissues.15
Overexpression studies and various Vav gene knockout mice have
revealed both unique and redundant roles of the 3 Vav family
members in lymphoid cells.16 The phosphorylation of Vav proteins
on specific tyrosine residues leads to conformational changes
required for binding to GTPase effectors.14 Vav1 has been shown to
exist as a complex with both p190- and p210-BCR-ABL,17 with
uncertain significance. Whether other Vav proteins complex BCR-
ABL is not known.
In the present study, we explored the upstream mechanism of
p190-BCR-ABL–dependent Rac activation through the Vav GEF
family members. We show that, although both Vav1 and Vav3 are
hyperactivated in primary human and murine p190-BCR-ABL
B-ALL, Vav3-deficient leukemogenesis induced by p190-BCR-
ABL is delayed. The proliferation and survival of B-cell progeni-
tors is impaired by genetic loss of Vav3 and can be reverted by its
reintroduction, and compensatory Vav3 up-regulation induced by
genetic combined deficiency of Vav1 and Vav2 translates into
increased survival and expansion ex vivo. Vav3 deficiency reduces
p190-BCR-ABL–induced Rac GTPase activation and decreases
proliferation and Vav3-deficient p190-BCR-ABL murine and
human B-cell progenitors have enhanced apoptosis associated with
augmented expression of Bad and Bik and the downstream
effectors Bax and Bak. Our results demonstrate that Vav3 is a
critical GEF in p190-BCR-ABL–mediated activation of Rac
GTPase and down-regulation of proapoptotic signals required for
leukemogenesis. We also demonstrate that Vav3 deficiency collabo-
rates with TKI in the inhibition of leukemogenesis in vivo.
Therefore, the results of the present study suggest that Vav3 may be
a useful therapeutic target in p190-BCR-ABL B-ALL.
Methods
Animals
Vav-deficient mice16 and Rac2-deficient mice18 have been described
previously. Vav1/;Vav2/ mice were generated by intercrossing. All
mutant mice had been backcrossed  10 generations into C57Bl/10 or
C57Bl/6 mice. Six- to 8-week-old female wild-type (WT) C57Bl/6 and
C57Bl/10 mice were obtained commercially (The Jackson Laboratory and
Harlan Laboratories) and used as donors and/or recipients of transduction/
transplantation models. The Cincinnati Children’s Hospital Medical Center
institutional animal care and use committee approved the protocol.
Human specimens
Umbilical cord blood (UCB) cells, normal BM, and B-ALL low-density
bone marrow (LDBM; p190-BCR-ABL or TEL-AML1) specimens were
obtained through institutional review board-approved protocols and donor
informed consent from Cincinnati Children’s Hospital Medical Center,
Universidad de Navarra (Spain), or Shanghai Children’s Medical Center
(China). All leukemic specimens contained a minimum of 80% blasts and
corresponded to specimens obtained at diagnosis or relapse.
Viral transduction
The retroviral vectors and generation methods have been used and
described previously.9 In brief, Ba/F3 or mouse LDBM were transduced
with bicistronic retroviral vectors (MIEG3)19 encoding BCR-ABL isoforms
p190 or p210 in the presence of 20 ng/mL of recombinant human IL-7
(PeproTech), 10 ng/mL of recombinant mouse SCF (PeproTech), and the
recombinant fragment of fibronectin, CH296 (Takara Bio) for 16 hours at
37°C. For the Vav3 rescue experiment, lentiviral particles encoding either
WT Vav3 (full-length) cloned in a pCDH1-MCS1-EF1-copGFP vector
(System Biosciences), or the empty vector, were used for stable expression
in p190-BCR-ABL B-cell lymphoid progenitors. Retroviral transduction
of human UCB CD34 cells was performed under conditions similar to
those used for murine cell transduction, but using recombinant human SCF
instead. Lentiviral transduction of UCB CD34 cells was performed using
2 rounds of infection with Vav3 shRNA-containing pLKO.1-puro-CMV-
tGFP vectors (Sigma-Aldrich) at a multiplicity of infection of 20.
Transplantation of transduced leukemic cells
LDBM cells from WT or gene-targeted mice lacking Vav or Rac were
isolated and transduced with either a retroviral bicistronic vector encoding
p190-BCR-ABL with enhanced green fluorescent protein (EGFP) as a
reporter or an empty vector solely expressing the reporter protein (Mock).
Transduced LDBM cells (1-3 106) were intravenously transplanted into
lethally (7 4.75 Gy) irradiated C57Bl/6 or C57Bl/10 mice. The multiplic-
ity of infection was kept low to allow 1 single copy of BCR-ABL per
transduced cell. Transduction efficiency of C57Bl/6 LDBM cells was not
significantly different between groups (3.3% 1.8%, 2.3% 1.1%, and
5.1%  2.3% for WT, Rac2/, and Rac3/ BM cells, respectively).
Transduction efficiencies of C57Bl/10 LDBM cells were not significantly
different among the groups (10.66% 2.12%, 10.86% 1.63%, and
11.5% 1.2% for WT, Vav3/, and Vav1/;Vav2/ LDBM cells,
respectively). Secondary recipients received the same irradiation dose and a
cell dose of 4  105 sorted EGFP B220cKit BM cells along with
3  106 normal, congenic C57Bl/10 BM cells. Peripheral blood was
retro-orbitally collected on day 21 and on subsequent days after transplanta-
tion for complete blood counts and leukocyte differentials to check the
engraftment of donor cells. Experimental mice were sacrificed when they
showed signs of extreme hunched posture with labored breathing and/or
symptoms of moribund or rear paralysis. BM and spleens were homoge-
nized and processed for flow cytometric analysis. The remainder of cells
were frozen for in vitro analysis.
CFU-proB assay
B-cell lineage colony-forming units (CFU-proB) were quantified after
9 days of culture of leukemic BM cells or sorted p190 BCR-ABL–
expressing B-cell progenitors in M3134 methylcellulose (StemCell
Technologies) supplemented with 30% FBS (for mouse B lymphoid
colony forming cells; StemCell Technologies), 2mM L-glutamine (Invitro-
gen), 1% antibiotics (penicillin-streptomycin; Invitrogen), 100M
-mercaptoethanol (Fisher-Scientific), 1% BSA (Sigma-Aldrich), 20 ng/mL
of recombinant mouse IL-7 (PeproTech), and 100 ng/mL of recombinant
mouse SCF (PeproTech).
For details on other methods, please see supplemental Methods
(available on the Blood Web site; see the Supplemental Materials link at the
top of the online article).
Results
Vav3 is activated in p190-BCR-ABL leukemia
Vav mediates the activity of protein TKs, including BCR-ABL,20 as
a result of the phosphorylation of a specific tyrosine residue in the
Vav DH domain. Vav1 has been shown to be activated in
BCR-ABL–expressing leukemias,17 but the level of activation of
Vav3 in BCR-ABL leukemias is unknown. In the present study, we
analyzed the level of Vav3 activation in human p190-BCR-ABL
B-lymphoblastic leukemias. All 7 LDBM samples from p190-BCR-
ABL B-ALL patients showed markedly increased levels of
expression and phosphorylation of Vav1 and Vav3 compared with
LDBM cells (7- and 14.3-fold increase, P  .05 and P  .01,
respectively) and CD34 cells (6.3- and 3.9-fold, respectively,
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P  .05) from normal controls (Figure 1A-B). In contrast, patients
with TEL-AML1 B-ALL BM cells (n	 3) showed normal activation
of Vav1 and minimal activation of Vav3 compared with p190-BCR-
ABL B-ALL cells (41-fold difference, P .01; Figure 1A-B).
We hypothesized that Vav3 activation plays an important and
nonredundant role in p190-BCR-ABL–mediated leukemogenesis.
To test this hypothesis, we used Vav gene-knockout mice in which
we transduced p190-BCR-ABL in LDBM cells. We first deter-
mined the leukemogenic effect of p190-BCR-ABL expression in
primary B-cell progenitors. LDBM cells from specific gene-deleted
murine models or WT mice were transduced with bicistronic
vectors expressing EGFP and p190-BCR-ABL (MSCV-p190-BCR-
ABL) or only EGFP (MIEG3), then cultured with IL-7 and SCF.21
The expression and activation of Vav family members were
analyzed by quantitative RT-PCR and phospho-immunoblot in
FACS-sorted B-220/c-kit/CD43/EGFP leukemic cells from
WT and Vav-deficient animals. Vav1 and Vav3, but not Vav2
mRNA, were detected in p190-BCR-ABL B-lymphoid progeni-
tors (supplemental Figure 1A-C). Expression of p190-BCR-ABL in
murine B-cell progenitors induced increased expression and activa-
tion of Vav1 and Vav3 (Figure 1C). We next examined the effect of
expression of p190-BCR-ABL in Vav3-deficient mice. In these
mice, p190-BCR-ABL expression in Vav3/ B-cell progenitors
was associated with up-regulation of both Vav1 and Vav2 mRNA
expression (supplemental Figure 1A-B), suggesting the existence
of compensatory mechanisms controlling the expression of Vav
proteins.
Vav3 is uniquely required for leukemia cell proliferation and
survival induced by p190-BCR-ABL, but not by p210-BCR-ABL
To assess the effects of Vav proteins on p190-BCR-ABL leukemo-
genesis, we analyzed whether the deficiency of these proteins
modulates the proliferation and/or survival of p190-BCR-ABL
B-cell progenitors. Deficiency of Vav3 impaired the expansion of
p190-BCR-ABL CFU-proB cells, whereas, paradoxically, the
combined deficiency of Vav1 and Vav2 increased the cumulative
expansion of B-cell progenitors (Figure 2A). Nontransformed
B-lymphoid progenitors showed limited expansion, which was
independent of their genotype (Figure 2A).
To analyze the cellular mechanism responsible for the differen-
tial effect of Vav3 and Vav1/Vav2 deficiencies on the expansion of
leukemic B-cell progenitors, we determined the proliferation and
survival of leukemic-transformed and nonleukemic-transformed
B-cell progenitors in vitro. We found that the absence of Vav3 was
associated with decreased cell-cycle progression (Figure 2B and
supplemental Figure 2). In contrast, combined Vav1 and Vav2
deficiency did not affect the proliferation of p190-BCR-ABL
B-cell progenitors significantly (Figure 2B). Interestingly, the
deficiency of Vav3 or Vav1/Vav2 did not modify cell-cycle entry of
mock-transduced B-cell progenitors significantly (Figure 2A-B and
supplemental Figure 2), suggesting that p190-BCR-ABL uses Vav3
as a signal mediator in cell proliferation. As expected, p190-BCR-
ABL expression enhanced survival of B-cell progenitors in culture
over 2 weeks (cell death in mock-transduced B-cell progenitors
 95%, Figure 2A and supplemental Figure 3A). Vav3 deficiency
impaired survival of p190-BCR-ABL B-cell progenitors signifi-
cantly, as assessed in liquid culture (Figure 2C) and in CFU-proB
cultures (supplemental Figure 3B-D), whereas combined Vav1/
Vav2 deficiency was associated with significantly decreased leuke-
mic progenitor death (Figure 2C and supplemental Figure 3B-D).
These data indicate that Vav3 controls the proliferation and survival
of leukemic lymphoid progenitors and that the survival of leukemic
B-cell progenitors is inversely affected by the absence of Vav1/
Vav2 expression.
Because Vav function may be subject to compensatory regula-
tion by the other Vav proteins, as suggested by the up-regulation of
Vav1 and Vav2 expression in Vav3-deficient B-cell progenitors
(supplemental Figure 1A-C), we analyzed whether the combined
deficiency of Vav1 and Vav2 modified Vav3 expression and/or
activation significantly. We found that the combined deficiency of
Vav1 and Vav2 up-regulated Vav3 expression (supplemental Figure
3E) and tyrosine phosphorylation (Figure 2D), as assessed in
whole-cell lysates and Vav3-immunoprecipitated specimens, respec-
tively. These data imply that Vav3 activation is responsible for the
Figure 1. Vav1 and Vav3 are overexpressed and
overactivated in p190-BCR-ABL ALL. (A) Representa-
tive immunoblot of phospho-Vav1 and phospho-Vav3 in
human cells. Lanes 1 through 3 are CD34 cells from
healthy donors; lanes 4 through 6 are LDBM cells from
healthy donors; lanes 7-9 are LDBM cells from patients
with TEL-AML1 B-ALL; and lanes 10 through 16 are
LDBM cells from 7 patients with p190-BCR-ABL B-ALL.
-actin expression analysis was used as a loading
control. Two independent experiments were run with the
same specimens. (B) Normalized phosphorylation of
Vav1 (empty bar) and Vav3 (solid bar) from the
samples in panel A. The ratio was generated by
dividing the densitometric value of each phosphory-
lated protein by that of -actin from the same sample.
Values represent average SEM. *P  .05; **P  .01.
(C) Immunoblot of phosphorylated forms (Vav1-
pTyr174 and Vav3-pTyr173) compared with total Vav1
and Vav3 in sorted murine B-220/c-kit/CD43/
EGFP B-cell progenitors transduced with either an
empty vector (MIEG3) or p190-BCR-ABL.
802 CHANG et al BLOOD, 26 JULY 2012  VOLUME 120, NUMBER 4
changes in cell-cycle progression and survival and suggest that the
increased survival observed in Vav1/Vav2–deficient, p190-BCR-
ABL–transduced B-cell progenitors is due to compensatory overex-
pression and overactivation of Vav3. We also analyzed whether
Vav3 and BCR-ABL coimmunoprecipitated in leukemic cells.
Vav3 and c-Abl immunoprecipitates of Ba/F3 cells transduced with
either p190-or p210-BCR-ABL did not show any significant
binding of Vav3 and BCR-ABL (supplemental Figure 4A-B),
suggesting that BCR-ABL–induced Vav3 activation does not
depend on direct binding.
To confirm the functional role of Vav3 in survival of leukemic
B-cell progenitors, we introduced Vav3 cDNA into Vav3/,
p190-BCR-ABL B-cell progenitors. Transduction of Vav3/
p190-BCR-ABLB-cell progenitors with a lentiviral vector express-
ing Vav3 (denoted Vav3/;Vav3 in Figure 3A) resulted in restora-
tion of Vav3 activation. Reintroduction of Vav3 reversed the state
of apoptosis induced by Vav3 deficiency significantly in p190-BCR-
ABL B-cell progenitors to a level similar to that in WT leukemic
cells (Figure 3B-C).
To verify the relevance of our findings in murine leukemic cells,
human UCB CD34 cells were retrovirally transduced with a
p190-BCR-ABL–internal ribosomal entry site (IRES)–EYEP vec-
tor and 3 different Vav3 shRNA-IRES-EGFP–containing vectors
and a nontargeting shRNA-IRES-EGFP–containing vector as a
control. The level of interference of Vav3 expression was con-
firmed in sorted EGFP/EYFP/CD34/CD19 cells (Figure 4A).
Increased levels of apoptosis of ex vivo–cultured cells were
inversely correlated with the level of expression of Vav3 (Figure
4B-C). These data support the conclusion that Vav3 is required for
p190-BCR-ABL murine and human leukemic cell survival and
that its activation may not depend on direct protein-protein
interaction.
Vav3 is required for complete leukemogenesis induced by
p190-BCR-ABL
As a consequence of these results, we next determined the effect of
Vav3 expression on p190-BCR-ABL B-ALL leukemogenesis in
vivo. Because loss of Vav proteins has been associated with
defective BCR signaling and defective naive B-cell survival,16 we
first determined whether there were significant quantitative or
functional defects in the BM B-cell progenitor content of Vav-
deficient mice that may have impaired the development of B-cell
lymphopoiesis at an early stage of differentiation. Vav3/ and
Vav1/;Vav2/ mice had a normal numbers of immunophenotypi-
cally defined B-cell progenitors (supplemental Figure 5A). Func-
tional analysis also confirmed normal numbers of progenitors
(supplemental Figure 5B). When mice were transplanted with
LDBM cells transduced with a retrovirus vector expressing
p190-BCR-ABL, greater than 90% of recipient mice developed
B-ALL. These mice maintained an expanded B220dim, CD19,
CD43/dim B-cell progenitor population in circulation (Figure 5A).
B-ALL mice showed both circulation and organ infiltration of
p190-BCR-ABL lymphoid cells leading to splenomegaly, lymph-
adenopathy, and CNS manifestations characterized by limb palsies.
The mean survival of congenic C57Bl/10 mice transplanted with
Figure 2. Loss of Vav3 impairs leukemic proliferation
and survival of p190-BCR-ABL B-cell progenitors.
(A) Expansion (fold) of in vitro–cultured B-cell progenitors
(CFU-proB) from WT (red lines), Vav1/;Vav2/ (green
lines), and Vav3/ (blue lines) cells transduced with
either p190-BCR-ABL (solid lines) or mock vector (MIEG3,
dotted lines). (B) S-phase fraction as assessed by bro-
modeoxyuridine incorporation of B-cell progenitors ex-
pressing either mock vector (hatched bars) or p190-BCR-
ABL (solid bars) on day 6 of in vitro culture. (C) Apoptosis
as assessed by annexin V binding of leukemic p190-BCR-
ABL B-cell progenitors on day 16 of in vitro culture.
(D) Representative example of immunoprecipitation and
Western blot of pTyr-Vav and total Vav3 in p190-BCR-
ABL B-cell progenitors from WT, Vav1/;Vav2/, and
Vav3/ mice. Lysates from 5  105 B-cell progenitors
were immunoprecipitated, loaded, and blotted with Abs
against phospho-tyrosine and Vav3. -actin expression
analysis from total lysate was used as a loading control
(n 	 3 independent experiments).
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WT, p190-BCR-ABL LDBM was 36.5 1.8 days. Survival was
significantly extended to 49.4 4.9 days in mice transplanted with
Vav3/, p190-BCR-ABL LDBM (Figure 5B, log-rank test,
P  .05). In contrast, loss of Vav1 (supplemental Figure 6) or
combined deletion of Vav1 and Vav2 did not prolong the survival of
recipient mice (33.7 2.3 days; Figure 5B, P 	 not significant.).
All recipient mice maintained peripheral B220/EGFP cells
from day 21 after transplantation throughout the study, con-
firming sustained engraftment of p190-BCR-ABL–expressing
B-lymphoid cells even in the absence of Vav proteins (Figure 5C).
Moreover, impaired leukemogenesis of sorted BM Vav3-deficient
B-cell progenitors (EGFP/ B220/cKit) was confirmed in
secondary recipients whose survival was significantly extended
(29.7 1.8 days) compared with secondary recipients of WT leu-
kemic cells (21.8 1.4 days, P  .01, Figure 5D). Interestingly,
mice transplanted with Vav3-deficient, p210-BCR-ABL–
transduced BM cells in which Vav3 was also activated (supplemen-
tal Figure 7A) developed similar phenotypically defined leukemias
as mice transplanted with p190-BCR-ABL (supplemental Figure
7B-C). However, the survival of Vav3/ p210-BCR-ABL recipi-
ents was similar to that of mice transplanted with WT p210-BCR-
ABL leukemic cells (supplemental Figure 7D).
To confirm the dispensable role of Vav3 in human B-ALL
induced by p210-BCR-ABL, we retrovirally transduced human
UCB CD34 cells with p210-BCR-ABL and with Vav3 shRNA-
containing lentiviral vectors. Similar to p190-BCR-ABL–trans-
duced CD34/ CD19 cells, Vav3 expression in shRNA–
transduced, p210-BCR-ABL–expressing CD34/CD19 cells was
also silenced (supplemental Figure 8A). However, the level of
p210-BCR-ABL leukemic cell apoptosis was not changed (supple-
mental Figure 8B-C), suggesting that the Dbl- and/or pleckstrin-
homology domains of p210-BCR-ABL may overcome the defi-
ciency of Vav3 activation and that Vav3 activation may be
dispensable for p210-BCR-ABL leukemogenesis. These data sug-
gest that Vav3, but not Vav1 or Vav2, is specifically required for
leukemogenesis induced by p190-BCR-ABL.
Vav3 deficiency impairs the Rac GTPase signaling pathway
in vivo
Both p190 and p210 forms of BCR-ABL activate small GTPases,
including Rac, Rho, and Ras GTPases (supplemental Figure 9). We
then analyzed whether Vav3 is required for activation of small
GTPases in p190-BCR-ABL expressing B-cell progenitors. We
observed that the activation of total-Rac, Rac-2, Cdc42 and Rho
were diminished in the absence of Vav3 in B-ALL cells harvested
from murine leukemias (Figure 5E). On the other hand, the
activation of Ras was not reduced in Vav3-deficient p190-BCR-
ABL leukemic B-cell progenitors (Figure 5F). This result is
consistent with previous observations that Ras is not a direct
substrate of Vav.22 These data also indicate that Vav3 is necessary
for full activation of Rho GTPases by p190-BCR-ABL in
B-lymphoid progenitors.
Among the Rho GTPases, we showed previously that Rac,
especially Rac2, is critical in the proliferation and survival of
p210-BCR-ABL CML leukemic stem cells,9,10 whereas the single
deficiency of Rac1 did not impair their leukemogenic ability in
vivo.9 To determine whether Vav3 plays a role as a GEF for Rac2 in
p190-BCR-ABL B-cell progenitors, we performed an effector
pull-down assay of GST-bound recombinant small GTPases. We
found that Rac2 to a higher degree, Rac1, Rho, and Cdc42 only
marginally bind Vav3 from lymphoblastic leukemic p190-BCR-
ABL–expressing cells (Figure 5G). K-Ras did not bind Vav3
(Figure 5G). A dominant-negative mutant of Rac2 (Rac2D57N,
nucleotide-free and with an ability to act as a GEF sink)23 has
increased binding to Vav3 (Figure 5G). In combination with the
small GTPase pull-down data (Figure 5E-F), these data strongly
suggest that Rac/Rho, and specifically Rac2, bind and are activated
by Vav3 in p190-BCR-ABL B-cell progenitors.
To determine the role of p190-BCR-ABL–induced Rac activa-
tion in leukemogenesis, we analyzed the role of Rac2, which
strongly binds to Vav3 (Figure 5G), and Rac3, which has been
implicated in BCR-ABL leukemia,24 in in vivo leukemogenesis.
Deficiency of Rac2, but not Rac3, delayed p190-BCR-ABL
Figure 3. Expression of transgenic Vav3 rescues
Vav3-deficient, p190-BCR-ABL leukemogenic cell
survival. (A) Representative example (n 	 4) of pVav3
and Vav3 expression in WT or Vav3/ p190-BCR-ABL
B-cell progenitors transduced with either empty vector
(WT; Mock or Vav3/; Mock) or Vav3 (WT;Vav3 or
Vav3/;Vav3). The level of Vav3 phosphorylation (pVav3/
Vav3 density ratio) is presented normalized to the WT;
Mock value. (B) Apoptosis as determined by annexin V
binding of transduced B-cell progenitors (day 15 of
culture). **P  .005; ***P  .001. Each experiment was
done in triplicate and data are represented as means
 SD. (C) Representative example of FACS analysis of
annexin V binding.
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leukemogenesis and prolonged mean survival time (54.6 3.0,
84.8 18.2, and 54.9 4.6 days for mice transplanted with WT,
Rac2/, and Rac3/ p190-BCR-ABL–transduced LDBM, respec-
tively, P  .05 for comparison between mice engrafted with WT vs
Rac2/ LDBM; Figure 5H). Similar to previous data in a model of
p210-BCR-ABL myeloproliferative disease,9 Rac2-deficient mice
showed levels of EGFP/B220 cells in peripheral blood compa-
rable with that in recipients of WT-transduced cells until their death
(supplemental Figure 10). The contents of B-cell progenitors in
BM of Rac2/ donor mice was normal, suggesting that the lack of
a target cell population was not responsible for the delayed latency
of leukemia (supplemental Figure 11A-B). These data confirm the
role of Rac2 in p190-BCR-ABL–induced leukemogenesis and
phenocopy the survival advantage of Vav3-deficient leukemias.
Vav3 is required to maintain the balance between survival and
death signals in p190-BCR-ABL B-ALL
To address the signaling pathways responsible for Vav3-dependent
leukemic B-cell progenitor survival, we explored the molecular
mechanism of increased apoptosis in Vav3/ leukemic B-cell
progenitors. Whereas activation of Akt was not consistently altered
by Vav3 deficiency (Figure 6A), activation of p21-activated kinase
(PAK), a direct effector of Rac GTPases, was decreased markedly
in p190-BCR-ABL Vav3/ B-cell progenitors (Figure 6A). In
contrast, the activation of the adaptor protein CrkL, which binds
ABL directly, was not changed in the absence of Vav3 (Figure 6A).
BCR-ABL–dependent signals are known to modulate the prosur-
vival proteins of the Bcl-2 family. Bcl2 family members have been
suggested as therapeutic targets in BCR-ABL leukemias.25 To
determine whether Vav3-dependent survival of p190-BCR-ABL
B-ALL cells was mediated by Bcl2 family proteins, we analyzed
the effect of Vav3 deficiency on the expression of Bcl2 family in
primary p190 BCR-ABL leukemic B-cell progenitors from B-ALL
mice. There was a significant increase in the expression of death
signals in Vav3-deficient, p190-BCR-ABL B-cell progenitors in
vitro (supplemental Figure 12) and leukemic blasts in vivo (Figure
6B-C,E). Vav3/ p190-BCR-ABL B-ALL cells showed in-
creased expression of cleaved caspase-3, confirming apoptotic cell
death associated with increased expression of the proapoptotic
proteins Bax, Bak, and the BH3-only molecule Bik (Figure 6B,E).
Although the level of expression of Bim, another BH3-only
molecule, was not changed in Vav3-deficient B-ALL primary
tumors (Figure 6B), the expression of all 3 isoforms of Bim was
up-regulated significantly in cultured p190-BCR-ABL B-cell
progenitors (supplemental Figure 12), suggesting that an interplay
of in vivo signals may reverse Bim up-regulation induced by Vav3
loss of function. In addition, Bad mRNA and protein expression
was increased markedly in Vav3-deficient, p190-BCR-ABL B-cell
progenitors (Figure 6C,E and supplemental Figure 13). Bad
inactivation prevents association of Bad with Bcl2/Bcl-xL and
promotes cell survival. To address whether Vav3 deficiency is
associated with inactivation of Bad, we analyzed 2 specific sites of
Bad phosphorylation that result from alternative kinase pathways.
The level of phospho(Ser136)-Bad which is the result of PAK/Akt
pathway activation,26,27 was reduced significantly (Figure 6C,E), in
agreement with decreased PAK activation. However, the level of
phospho(Ser112)-Bad, which is dependent on p90RSK28 and
protein kinase A activation,29 was not changed (Figure 6C,E). The
Figure 4. Level of Vav3 expression is correlated with
cell death of p190-BCR-ABL transduced human CD34
cells. (A) Relative Vav3 mRNA expression was assessed
by real-time quantitative RT-PCR. Three different
shRNA-containing vectors were lentivirally transduced
and different levels of Vav3 gene interference were
detected cycle threshold (Ct  50, undetectable level).
(B) Apoptosis as determined by annexin V binding in
shRNA-transduced p190-BCR-ABL human B-cell pro-
genitors (day 15 of culture). ***P .001 from day 10 onward
for shRNA #1 (red symbols and line) and from day
13 onward for shRNA #2 (green symbols and line) and
shRNA #3 (blue symbols and line) versus control (ANOVA
test). Black symbols and line denote control shRNA
values. (C) Representative example of FACS analysis of
annexin V binding. Annexin V binding was analyzed on
EGFP (shRNA)/EYFP (p190-BCR-ABL)/CD19/CD34
cells.
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expression of antiapoptotic Bcl-xL and Bcl-2 were similar in
Vav3/p190-BCR-ABL B-ALL cells compared with their WT
counterparts (Figure 6D). These data indicate Vav3 modulates the
balance between pro- and antiapoptotic signals in p190-BCR-ABL–
expressing leukemia cells. Moreover, these results suggest that the
up-regulation of BH3-only molecules induced by the loss of Vav3
can counteract the increased survival of leukemic cells resulting
from BCR-ABL–dependent activation of prosurvival Bcl-2 family
members.
Vav3 deficiency collaborates with TKIs to impair survival of
leukemic lymphoid progenitors in vitro and in vivo
BCR-ABL TK activity is considered to be responsible for BCR-
ABL transformation. However, TKIs targeting BCR-ABL have
only shown a transient and modest effect on the long-term survival
of BCR-ABL B-ALL patients.30 Therefore, we examined whether
TK inhibition and deficiency of Vav proteins collaborated in terms
of inhibition of p190-BCR-ABL leukemic cell proliferation while
cultured in presence of SCF and IL-7. To allow similar numbers of
starting CFU-proB cells in the original inocula, p190-BCR-ABL–
transduced LDBM cells were cultured for 3 days (a selected period
of time when Vav3 deficiency has not yet induced a loss of B-cell
progenitors, as demonstrated in Figure 2A), then sorted for EGFP
B-cell progenitors and plated in methylcellulose with different
concentrations of imatinib or dasatinib. Loss of Vav3 collaborated
with TK inhibition by imatinib (Figure 7A-B) at doses of 1M or
higher to inhibit B-cell progenitor growth. In contrast, the com-
bined deficiency of Vav1 and Vav2 attenuated the effect of imatinib
on B-cell lymphoid progenitor growth and demonstrated an
antagonistic effect (Figure 7A-B), which is in agreement with our
previous data on the pathogenic role of activated Vav3 in the
context of Vav1/Vav2 combined deficiency. Vav3 deficiency also
collaborated with dasatinib, which is a combined BCR-ABL and
Src family inhibitor, to prevent the growth of leukemic B-lymphoid
progenitors (Figure 7C-D). Interestingly, the combined deficiency
of Vav1 and Vav2 also collaborated with dasatinib to inhibit B-cell
progenitor outgrowth (Figure 7C-D), suggesting that the Src family
kinase inhibitory activity of dasatinib may antagonize the function
of hyperactivated Vav3.
Figure 5. Vav3 deficiency delays p190-BCR-ABL in-
duced B-ALL leukemogenesis and is associated with
reduced activation of Rac. (A) Circulating p190-BCR-
ABL–expressing B-cell progenitors in murine B-ALL trans-
duction/transplantation model as determined by FACS
analysis. (B) Survival of mice transplanted with 3  106
p190-BCR-ABL LDBM cells from WT (n 	 22, black),
Vav3/ (n 	 19, green), or Vav1/;Vav2/ (n 	 6, red)
mice. *P  .05 (log-rank test). (C) Percentage of EGFP/
B220 cells in the peripheral blood of WT (C57Bl/10,
empty bars), Vav1/;Vav2/ (gray bars) or Vav3/
(black bars) mice shown in Figure 1B at different time
points. (D) Representative experiment of 2 experiments
with similar results, showing survival of secondary mice
transplanted with sorted leukemic B-cell progenitors from
primary B-ALL mice engrafted with p190-BCR-ABL WT
(black) or p190-BCR-ABL, Vav3-deficient (green) cells.
EGFPB220CD43, cKitdim cells 4  105) were iso-
lated and transplanted along 5  106 normal congenic
BM cells into secondary recipients (C57Bl/10, n 	 9 for
each group). **P  .01 (log-rank test). (E-F) Representa-
tive examples of effector binding domain pull-down as-
says for total Rac, Rac2, Cdc42, and Rho (E) and Ras
(F) of p190-BCR-ABL–expressing murine B-ALL BM cells
(n 	 3 independent experiments). Relative activation ra-
tio (GTP-bound GTPase/total GTPase) normalized to the
WT value is provided below each panel. (G) Representa-
tive example of Vav3 (effector) binding assays. Lysate
from p190-BCR-ABL BaF/3 was incubated with GST
alone, GST-fused Rac1, Rac2, Rac2D57N, Cdc42, or
K-Ras (2 g) and 10 L of suspended glutathione-
agarose (n 	 3 independent experiments). (H) Kaplan-
Meier survival curves of mice transplanted with p190
BCR-ABL–transduced LDBM cells from Rac2/ (n 	 10,
green line), Rac3/ (n 	 22, blue line), or WT mice
(n 	 17, brown line). *P  .05 (log-rank test).
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To understand mechanistically the signaling mechanisms of
collaboration between Vav3 and the TK domain of ABL, we
analyzed the activation of Pak and CrkL, which has been shown to
be crucial in BCR-ABL–induced leukemogenesis,31 in TKI-treated,
sorted leukemic B-cell progenitors. Both Vav3 deficiency and
incubation with TKIs are highly effective in impairing Pak
activation in lymphoblastic progenitors, and seem to have an
additive effect (Figure 7E). Unlike TKIs32 or Vav3 deficiency
alone, incubation with either imatinib or dasatinib synergized with
Vav3 deficiency to completely abrogate activation of CrkL (Figure
7E). These data strongly suggest that the TK activity of p190-BCR-
ABL and Vav3 activity collaborate in Pak activation and that they
are functionally redundant for activation of CrkL.
Collaboration of Vav3 deficiency and administration of TKIs
was also analyzed in vivo. Vav3 deficiency collaborated with administra-
tion of imatinib to extend the survival of mice transplanted with either
WT or Vav3/ p190-BCR-ABL–transduced LDBM cells (mean
survivals times, 52.0 6.8 days and 77.3 5.7 days, respectively,
P  .05; Figure 7F) compared with mice receiving no TKI
administration (Figure 5B). Whereas dasatinib administration ex-
tended the survival of mice transplanted with WT, p190-BCR-ABL–
transduced LDBM cells significantly (average survival time,
65.2  5.2 days) compared with mice treated with imatinib
(P  .05), the effect of Vav3 deficiency (average survival time,
72.3 2.2 days) was more modest and did not reach statistical
significance (Figure 7F). Analysis of Vav3 activation in leukemic
EGFP BM cells from imatinib- and dasatinib-treated WT de-
ceased animals demonstrated a modest inhibition of Vav3 activa-
tion, which was more significant for dasatinib-treated leukemias,
albeit not abrogated (Figure 7G). Vav3 expression was not modi-
fied by imatinib or dasatinib treatment. These data suggest that
Vav3 activation in vivo may depend on multiple signals, including
the ABL TK of p190-BCR-ABL and Src kinase activity.
The results of the present study suggest that TKI therapy does
not suffice to prevent Vav3 activation and that Vav3 deficiency
collaborates with TKIs to inhibit Pak and CrkL to inhibit leukemo-
genesis in vitro and in vivo.
Discussion
Our previous studies have demonstrated that hyperactivation of
Rac GTPases, and specifically Rac2, are key signals in BCR-ABL–
induced transformation and leukemogenesis.9,10 Lymphoid transfor-
mation of BCR-ABL–expressing progenitors has been associated
with genomic instability and mutagenesis through mechanisms that
are not well characterized but in which Rac activation has been
suggested to play a role through the generation of reactive oxygen
species.12
In the presents tudy, we explored the upstream mechanism of
Rac activation by the short form of BCR-ABL, which lacks an
activating DH domain. We found that Vav3 plays a crucial role in
p190-BCR-ABL–mediated leukemogenesis, proliferation, and sur-
vival. Our data show that p190-BCR-ABL up-regulates both Vav1
and Vav3 expression and activation, but only the deficiency of Vav3
attenuates the transformation phenotype regarding progenitor pro-
liferation, especially the survival of B-cell progenitors, the putative
leukemia-initiating cells in this disease. Vav3 deficiency delays
p190-BCR-ABL–induced but not p210-BCR-ABL–induced lym-
phoid leukemogenesis in vivo. The delay in lymphoid leukemogen-
esis induced by the loss of Vav3 phenocopies the deficiency of
Rac2, indicating that whereas the functional relevance of Vav3
activation relates specifically to p190-BCR-ABL but not p210-BCR-
ABL expression, the dependence on Rac2 activity seems to affect
to both p210-BCR-ABL leukemia9,10 and p190-BCR-ABL leuke-
mia (Figure 5H). Vav3 deficiency impairs cell-cycle progression
and survival mediated by p190-BCR-ABL, unlike a combined
deficiency of Vav1 and Vav2, which leads to increased Vav3
activation with either no effect or modest enhancement of leukemic
transforming phenotypes. Moreover, the survival impairment in-
duced by Vav3 deficiency can be rescued by exogenous expression
of Vav3 in Vav3/ lymphoid progenitors, ruling out a developmen-
tal defect associated with Vav3 deficiency in primary murine cells.
Figure 6. Vav3 modulates Bcl-2 family for p190-BCR-ABL leukemic cell
survival. (A) Representative immunoblots of p-AKT, p-PAK, and p-CrkL in B-cell
progenitors from primary murine B-ALL BM cells. -actin expression analysis was
used as a loading control. (B) Representative immunoblots of Bax, Bak, Puma, Bim
(EL, L, and S isoforms are identified), and Bik in p190-BCR-ABL B-cell progenitors.
Cleaved caspase-3 expression was analyzed to confirm proapoptotic status of analyzed
cells and -actin was used as a loading control. (C) Level of expression and phosphoryla-
tion of Bad in WT and Vav3/ leukemic B-cell progenitors. (D) Representative immuno-
blots of Bcl-xL and Bcl-2 in p190-BCR-ABL WT or Vav3/ B-ALL murine BM cells.
-actin was used as a loading control (n 	 3 independent experiments). (E) Normal-
ized expression levels of proteins presented in panels B and C (n 	 3 independent
experiments). Vav3-deficient, p190-BCR-ABL primary B-ALL BM cells (solid bars)
were normalized to their WT counterparts (empty bars). Results are shown as means
 SD. *P  .05.
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To understand the role of Vav3 signaling in p190-BCR-ABL
cell survival, we investigated whether Vav3 coimmunoprecipitated
with BCR-ABL and the downstream pathways of Vav3, specifi-
cally the direct effector of Rac GTPase, and Ras activation. First,
unlike Vav1,20 we found that Vav3 did not coimmunoprecipitate
with either p190-BCR-ABL or p210-BCR-ABL, but as is the case
with p210-BCR-ABL leukemia,9,11 Rac GTPases are activated in
p190-BCR-ABL leukemia (supplemental Figure 9). Therefore,
Vav3 activation seems not to depend on direct binding to BCR-
ABL. Second, we found that whereas Ras activity was not affected
by Vav3 deficiency, Rac activation was decreased significantly in
Vav3-deficient, p190-BCR-ABL lymphoblastic leukemias. Bio-
chemically, Vav3 strongly binds Rac2, Rac1, RhoA, and, margin-
ally, Cdc42 in p190-BCR-ABL–expressing lymphoid leukemic
cells. A dominant-negative mutant of Rac2 (Rac2D57N) with
significantly impaired GTP binding ability resulting from a mark-
edly enhanced rate of GTP dissociation is able to pull down all
Vav3, suggesting that Rac2 is susceptible of being activated by
Vav3. Furthermore, Rac2 but not Rac3 deficiency phenocopies
Vav3 deficiency in extending the survival of mice transplanted
with p190-BCR-ABL–transduced LDBM cells. In agreement with
our previously published data on the role of Rac proteins in
p210-BCR-ABL myeloproliferative disease development9 and
the role of Rac2 specifically in leukemic stem cell–initiated
myeloproliferative disease,10 the results of the present study further
strengthen our understanding of the crucial role of Rac proteins in
the initiation and/or progression of BCR-ABL leukemias. Al-
though we cannot rule out a non-GEF activity of Vav3 similar to
that for Vav1 in other cell contexts,33 our data strongly suggest that
Vav3 acts as a GEF of Rac2.
BCR-ABL induces cell proliferation and suppresses apopto-
sis through different mechanisms, including inhibition of proapo-
ptotic molecules such as Bad.34 Bad controls the life-death
switch and promotes apoptosis and cell-cycle arrest by antago-
nizing the prosurvival and cell-cycle progression activity of
Bcl-2/Bcl-xL proteins35 or by activating proapoptotic Bax or
Bak directly.36 Bad has been identified as an overexpressed gene
in imatinib-resistant CML37 and in Rac2-null mast cells.38
Whereas the expression levels of Bad are important in the
regulation of its function, Bad activity also depends on its
Figure 7. Loss of Vav3 sensitizes p190 BCR-ABL
B-cell progenitors to kinase inhibitor drug treatments
in vivo and in vitro. (A) B-cell progenitor frequency
(CFU-proB) of p190-BCR-ABL–transduced LDBM cells
in the presence or absence of different concentrations of
imatinib. Transduced LDBM cells were cultured for 9 days
in methylcellulose with the indicated doses of imatinib.
Results are shown as means  SD of 2 independent
experiments performed in triplicate. *P  .05. (B) Normal-
ized B-cell progenitor cell frequency with respect to
WT cells from the same cultures shown in panel
A. *P  .05; **P  .01. (C) B-cell progenitor frequency
(CFU-proB) pf p190-BCR-ABL–transduced LDBM cells
in the presence or absence of different concentrations of
dasatinib carried out as in panel A. Two independent
experiments were performed in triplicate. *P  .05.
(D) Normalized B-cell progenitor frequency (CFU-proB)
with respect to WT cells from the same cultures shown in
panel C. B-cell progenitor frequencies of WT cells are
depicted by black lines (A,C) or empty bars (B,D);
Vav1/;Vav2/ are depicted by red lines (A,C) or gray
bars (B,D); and Vav3/ are depicted by green lines
(A,C) or black bars (B,D). (E) Representative example of
immunoblot of p-PAK and p-CrkL in sorted B-cell progeni-
tors from primary mouse LDBM cells transduced with
p190-BCR-ABL. Sorted leukemic B-cell progenitors were
pretreated with 5M imatinib, 10nM dasatinib, or no drug
(untreated) for 2 hours in vitro. -actin expression was
analyzed as a loading control (n 	 2 independent experi-
ments). (F) Kaplan-Meier survival curves of p190-BCR-
ABL–induced B-ALL mice treated with either imatinib
(solid lines) or dasatinib (dotted lines). WT (black solid
line, n 	 13) and Vav3-deficient (green solid line, n 	 13),
p190-BCR-ABL B-ALL mice were treated with daily
doses of imatinib for up to 90 days. WT (black dotted line,
n 	 10) and Vav3-deficient (green dotted line, n 	 15),
p190-BCR-ABL B-ALL mice were treated with dasatinib
for 75 days. *P  .05 between imatinib-treated WT B-ALL
mice and Vav3/B-ALL mice; #P  .05 between imatinib-
treated WT B-ALL mice and dasatinib-treated WT B-ALL
mice (log-rank test). (G) Representative examples of
immunoblot of Vav3 activation (p-Vav3) and expression
(Vav3) in EGFP B cells from the BM of leukemic animals
transplanted with WT, p190-BCR-ABL–expressing
BM cells and left untreated or treated with imatinib or
dasatinib (n 	 2 mice per group in 1 of 2 independent
experiments).
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phosphorylation state. Bad phosphorylation at Ser112 or Ser135/
136 induces ubiquitination and protein degradation.39 Our data
suggest that Vav3 deficiency regulates cell-cycle arrest and
apoptosis that is altered in p190-BCR-ABL leukemogenesis.
PAK proteins are major effectors of activated Rac and activated
PAK has been shown to phosphorylate and inactivate Bad.40
PAK may also phosphorylate Bik, resulting in the survival of
B-lineage lymphoid cells.41 This signal pathway has also shown
to be responsible for cytoskeletal rearrangements and cell
motility in B-lineage lymphoid cells.42 In the present study,
diminished Rac (including Rac2) activation in Vav3-deficient
B-ALL was correlated with decreased PAK activation, an
increased Bad/pBad ratio, and a deficiency of Rac2 that
phenocopied the increased survival of recipient mice of Vav3-
deficient, p190-BCR-ABL leukemic cells. In contrast, we found
that the expression of Bcl-2 and Bcl-xL was not altered in
Vav3-deficient leukemic cells. These data suggest that Vav3
activation may use Rac2/PAK/pBAD as a signaling pathway in
p190-BCR-ABL leukemic cell survival.
Although the level of inactive phospho(Ser112)-Bad, a conse-
quence of phosphorylation by p90RSK28 or protein kinase A,29 was
maintained (Figure 6C,E), the level of phospho(Ser136)-Bad, a
target of PAK and Akt kinase activities, was reduced to promote
cell death.26 In the context of decreased PAK activation with
unchanged Akt activation, these results strongly suggest that
PAK/Bad are downstream signaling targets of Vav3 activity in the
context of p190-BCR-ABL leukemogenesis. Increased expression
of Bad, Bik, Bax, and Bak in Vav3-deficient cells represents
additional negative regulation on lymphoid progenitor proliferation
and survival. These data suggest that Vav3 deficiency regulates
cell-cycle progression and survival negatively, which counteracts
the survival signals induced by BCR-ABL.
Current therapeutic strategies in p190-BCR-ABL B-ALL are
based on combination therapy regimens incorporating continuous
imatinib treatment with intensive multiagent chemotherapy, radio-
therapy, and stem-cell transplantation in selected patients.43 A poor
response and/or resistance to TKI therapy is believed to be due to
mutations in ABL. For this reason, current efforts are focused on
the development of new drugs with ABL TKI activity against
BCR-ABL mutants.44 Dasatinib, a multitargeted kinase inhibitor
with specificity for BCR-ABL, Src family kinases, and other TKs,
has shown an advantage over classic ABL TKIs through binding to
mutation-induced conformational dynamics of the ABL kinase
domain.45 Dasatinib shows significant antileukemic activity and is
increasingly used in the treatment of BCR-ABL B-ALL.46
Unfortunately, like imatinib, long-term durable responses are not
observed with single-agent therapy47 and effects on survival largely
depend on combinatorial therapies. With both imatinib and dasat-
inib, resistance to TKI therapy has been shown to occur in a
significant number of patients. Among the downstream mecha-
nisms found to be activated in TKI therapy resistance, Bcl-2
overexpression or loss of Bim and Bad expression48 and gene
deletion of CDKN2A and CDKN2B in BCR-ABL leukemia
cell–initiating cell subpopulations has been associated with aggres-
sive leukemic growth.6 These genetic alterations evolve even in
presence of effective TKI and are dependent on cytokine signal-
ing,49 suggesting that signals independent of BCR-ABL TK
activity may be responsible for cell transformation, proliferation
and survival in BCR-ABL leukemia.
The results of the present study show that the combination of
Vav3 deficiency and imatinib extends animal survival in vivo and
results in the inhibition of B-cell progenitor expansion in vitro,
even in the presence of lymphoid cytokines. As expected from our
previous data, which showed that combined Vav1/Vav2 deficiency
induces overexpression and hyperactivation of Vav3, the combined
deficiency of Vav1 and Vav2 showed an opposite effect, inducing
B-cell progenitor expansion in vitro. Furthermore, the additive
effect of imatinib or dasatinib and Vav3 deficiency strongly suggest
that Vav3 controls the activation of BCR-ABL–signaling path-
ways, and loss of Vav3 collaborates with TK inhibition to revert
leukemic progenitor transformation. The combined deficiency of
Vav1 and Vav2 antagonizes the inhibitory effect of imatinib on
B-cell progenitor proliferation, which may be explained by basal
Vav3 up-regulation of Vav1/Vav2–deficient leukemic progenitors.
Interestingly, dasatinib, an inhibitor of a much broader spectrum of
kinase targets, collaborates with the combined deficiency of Vav1
and Vav2, suggesting that the inhibitory activity of dasatinib on
targets other than the ABL TK domain may affect active pathways
distinctly secondary to increased Vav3 activation. We have found
that in vivo administration of imatinib or further dasatinib inhibits
leukemic Vav3 activation, but does not abrogate it, indicating that
Vav3 activation depends partly on ABL TK and Src kinase
activities, but also on other in vivo signals. The unidentified signals
may originate in the BM microenvironment because, as we have
shown previously,50 the abrogation of the expression of the full
BCR-ABL fusion protein induces B-ALL apoptosis and cures
leukemia. The mechanism of collaboration between Vav3 and ABL
TK signaling in p190-BCR-ABL B-cell progenitors may relate to
their concerted action on Pak and CrkL activation. Whereas Vav3
deficiency impairs Pak activation significantly, the addition of TKI
completely abrogates its activation. Similarly to incubation with
TKIs,32 the isolated deficiency of Vav3 does not inhibit CrkL
activation significantly. However, the combination of either ima-
tinib or dasatinib with Vav3 deficiency abrogates CrkL activation
completely. These data may provide an explanation for the clinical
resistance to TKI observed in p190-BCR-ABL B-ALL.
In summary, the results of the present study show that Vav3 is a
pivotal downstream target in p190-BCR-ABL signaling and acts as
a critical determinant of leukemic cell survival. Deregulated
expression and activation of Vav3 is associated with leukemic
transformation. Loss of Vav3 alone resulted in increased leukemic
cell death and impaired disease progression in vivo. Targeted
specific inhibition of Vav3 activity may lead to the loss of leukemic
cells through decreased survival and, together with TKI therapy,
may improve the treatment of p190-BCR-ABLALL.
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